Uniqure N.V. (QURE) Stock Price, Quote & News

Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 20 240 6000

Website: www.uniqure.com

Address:

Paasheuvelweg 25, Amsterdam, Netherlands

DakkelBoto Oct. 7 at 8:25 AM

$QURE $SPRB good play here. Will take profits @$300 sell half or maybe 75%

0 · Reply

Jadek6 Oct. 7 at 12:12 AM

$AGIO..traders are always losers… Take Matt Kapusta , Brain Goff , both CEO’s $QURE Both sold, rather than buy their options and bank them Each one having sold their sizeable chunks at lower prices Keep up your one night stands, they always get more expensive , knowing your degenerate behavior !!!

0 · Reply

TortulTH Oct. 6 at 11:53 PM

$QURE Cya at 40$

0 · Reply

TheBlaze Oct. 6 at 9:23 PM

$ZVRA $SPRB $QURE $OPEN Come on over to $ZVRA our party is just getting started! I smell a new 52 week high coming soon! https://markets.financialcontent.com/stocks/article/marketminute-2025-10-6-zevra-therapeutics-stock-soars-on-strong-performance-and-strategic-wins-what-it-means-for-investors

1 · Reply

flow2me Oct. 6 at 8:49 PM

$QURE would love to buy around 30-35(last time I picked up there)

0 · Reply

BaringsTrading Oct. 6 at 8:01 PM

$QURE

0 · Reply

owltrading Oct. 6 at 7:48 PM

$QURE I really need this to sell off!

0 · Reply

Capitulation_0 Oct. 6 at 7:29 PM

$QURE haven't had a buyout lately... only therapy for huntington is here. worth 3x from here but i think they'll sell for 2x current price.

0 · Reply

UnoffensiveName Oct. 6 at 7:26 PM

$QURE dont say never. Llook at $SPRB 7 to 160 today.

0 · Reply

DakkelBoto Oct. 6 at 7:17 PM

$QURE I sold this for $SPRB this morning. Couldn’t complain

1 · Reply

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

Sep 25, 2025, 11:38 PM EDT - 11 days ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

Sep 25, 2025, 8:37 AM EDT - 11 days ago

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street

Sep 25, 2025, 7:23 AM EDT - 11 days ago

uniQure Stock Jumps On Positive News, But Risks Remain

Sep 25, 2025, 6:20 AM EDT - 11 days ago

UniQure: How QURE Stock Rises 10x To $500?

Sep 24, 2025, 4:37 PM EDT - 12 days ago

Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it

Sep 24, 2025, 4:24 PM EDT - 12 days ago

uniQure: Positive 3-Year AMT-130 Data Leads To Pre-BLA FDA Meeting And Beyond

Sep 24, 2025, 4:06 PM EDT - 12 days ago

uniQure Announces $200 Million Proposed Public Offering

Sep 24, 2025, 1:03 PM EDT - 12 days ago

uniQure N.V. - Special Call

Sep 24, 2025, 11:20 AM EDT - 12 days ago

QURE stock skyrockets 200% on ‘three' big news

Sep 24, 2025, 10:23 AM EDT - 12 days ago

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial

Sep 24, 2025, 7:28 AM EDT - 12 days ago

UniQure's brain disorder drug slows disease progression in trial

Sep 24, 2025, 7:10 AM EDT - 12 days ago

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

Sep 24, 2025, 7:05 AM EDT - 12 days ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease

Sep 5, 2025, 4:57 PM EDT - 4 weeks ago

uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data

Sep 5, 2025, 7:05 AM EDT - 4 weeks ago

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

Jul 30, 2025, 11:07 AM EDT - 2 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE NTLA RCKT

Jul 29, 2025, 9:07 PM EDT - 2 months ago

uniQure N.V. (QURE) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:05 AM EDT - 2 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

Jul 22, 2025, 7:05 AM EDT - 2 months ago

uniQure to Announce Second Quarter 2025 Financial Results

Jun 11, 2025, 8:00 AM EDT - 4 months ago

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

Jun 2, 2025, 7:05 AM EDT - 4 months ago

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

May 28, 2025, 4:56 AM EDT - 4 months ago

uniQure's AMT-130 Gene Therapy Warrants An Upgrade

May 19, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

AKTX CRBP

May 9, 2025, 10:16 PM EDT - 5 months ago

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:05 AM EDT - 5 months ago

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 8, 2025, 5:16 AM EDT - 5 months ago

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data

May 5, 2025, 4:05 PM EDT - 5 months ago

uniQure to Announce First Quarter 2025 Financial Results

Apr 21, 2025, 1:56 AM EDT - 6 months ago

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

Apr 19, 2025, 8:31 AM EDT - 6 months ago

uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting

Apr 17, 2025, 10:27 AM EDT - 6 months ago

Why Is Gene Therapy Developer uniQure Stock Trading Higher On Thursday?

Apr 17, 2025, 7:17 AM EDT - 6 months ago

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

Feb 27, 2025, 7:05 AM EST - 7 months ago

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

Feb 26, 2025, 1:47 AM EST - 7 months ago

uniQure N.V.: A Potential Huntington's Play

Feb 20, 2025, 3:07 PM EST - 8 months ago

uniQure: Gene Therapy Specialist Looks Set For Upside As Huntington's Approval Beckons

Feb 7, 2025, 1:04 PM EST - 8 months ago

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

Feb 7, 2025, 9:12 AM EST - 8 months ago

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

Feb 3, 2025, 7:05 AM EST - 8 months ago

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Jan 30, 2025, 7:37 AM EST - 8 months ago

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

Jan 8, 2025, 7:05 AM EST - 9 months ago

uniQure Announces Pricing of its Public Offering

Jan 7, 2025, 4:49 PM EST - 9 months ago

uniQure Announces Proposed Public Offering

Dec 30, 2024, 6:31 PM EST - 10 months ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

Dec 10, 2024, 7:05 AM EST - 10 months ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

$uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy$

Nov 21, 2024, 7:05 AM EST - 11 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 5, 2024, 7:05 AM EST - 11 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Sep 23, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 6, 2024, 3:03 AM EDT - 1 year ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 1, 2024, 7:05 AM EDT - 1 year ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

DakkelBoto Oct. 7 at 8:25 AM

$QURE $SPRB good play here. Will take profits @$300 sell half or maybe 75%

0 · Reply

Jadek6 Oct. 7 at 12:12 AM

0 · Reply

TortulTH Oct. 6 at 11:53 PM

$QURE Cya at 40$

0 · Reply

TheBlaze Oct. 6 at 9:23 PM

1 · Reply

flow2me Oct. 6 at 8:49 PM

$QURE would love to buy around 30-35(last time I picked up there)

0 · Reply

BaringsTrading Oct. 6 at 8:01 PM

$QURE

0 · Reply

owltrading Oct. 6 at 7:48 PM

$QURE I really need this to sell off!

0 · Reply

Capitulation_0 Oct. 6 at 7:29 PM

$QURE haven't had a buyout lately... only therapy for huntington is here. worth 3x from here but i think they'll sell for 2x current price.

0 · Reply

UnoffensiveName Oct. 6 at 7:26 PM

$QURE dont say never. Llook at $SPRB 7 to 160 today.

0 · Reply

DakkelBoto Oct. 6 at 7:17 PM

$QURE I sold this for $SPRB this morning. Couldn’t complain

1 · Reply

TruthTrader Oct. 6 at 6:59 PM

$QURE This reminds me of PMCB. It was selling around $3. They issued a secondary offering because they "needed the money." Salaries of course. Then CEO gave BS about wanting to "enhance shareholder value." Promised "BIG" things were coming. Sure years have gone by and it sells around $1. Enough to keep nasdaq compliance. Was on "Hopium." Hope it was going double digits. Never was going to happen. Got stuck into dead money for years. Never again. The stock had such little movement. I saw more movement with the concrete cracking in the front yard than this stock.

1 · Reply

DavidDayTrade Oct. 6 at 6:50 PM

$QURE looks like we can see 30s this week

2 · Reply

TruthTrader Oct. 6 at 6:47 PM

$QURE Let me give you just a brief example. AVIR-2.88--target: $9.00. MNKD 5.70 target $15. SCPH 5.7 target- $25. VRCA 4.59 Target $20. These biotechs always have high targets but NEVER get there. QURE is never going to get to $110. If it does then be prepared to sit on the stock for years. Maybe you have 5- 10 years to wait. I rather put my money into a momentum stock that has a lot more potential. When you jump aboard the phony momentum train in the end you get stuck. They spring secondaries on you and the stock drifts down. You sit on dead money. You just paid for management salaries. I have been doing a lot better in my investing skills by promising myself to never buy into two types of stocks. Biotech and Chinese. Never. Again.

0 · Reply

TruthTrader Oct. 6 at 6:30 PM

$QURE Why? Why buy when it is at its highs. Nothing is going to push it higher. They got their money and management gets a paycheck. The stock is going to descend back into the 40-30s. I 100 percent guarantee it. This never fails with biotech. I know lots of biotech companies with high targets that are not close to those target. The whole point was to push this higher so hedge funds could make their money too at the expense of individual investors. Why would you buy and sit on dead money for years to come.

1 · Reply

NextVersion Oct. 6 at 5:14 PM

$QURE A lot of catalysts coming. I would honestly expect most(or all) of this stocks gains to happen within a year’s time. Big potential buyout target. I would not be surprised at all to see an M&A announcement at the JPM conference in January. In fact, that’s probably the best time and place for an acquirer to do so.

0 · Reply

Capitulation_0 Oct. 6 at 5:03 PM

$QURE Roche, PFE, NVS should all be looking at this very hard... LLY too.

1 · Reply

DakkelBoto Oct. 6 at 4:57 PM

$QURE can we get to $60 already???

0 · Reply

Bullishbruk Oct. 6 at 3:48 PM

$QURE RSI needs to cool off $45-$47 will entertain

0 · Reply

Cicada_Boss_CicadaWay Oct. 6 at 3:32 PM

$QURE a break of $54 would be nice, this ticker is getting boring

0 · Reply

TruthTrader Oct. 6 at 3:07 PM

$QURE I don't take a much advise from Jim Crammer but his comment today was "I will not endorse it." This one has too many questions for me up here." Biotech has an almost perfect track record of bringing out news in order to get a secondary out in the market. They do it to have money to pay staff and management. Once they get their money and paychecks the stock just drifts back down. It will definitely happen here too. If you bought on the high end you could either wait and hope something good happens in a few years or get out now. It is not going much higher.

0 · Reply

Kmoy1776 Oct. 6 at 2:48 PM

$QURE of course they did. it benefits them to pump it all they can until they can dump.(says 60 days in the filing) if it dumps before then, they lose money. after that, they dump on retail who havent taken their profits like last time it pumped

0 · Reply

diagio Oct. 6 at 2:40 PM

$IXHL You want to see what a real pharma looks like? Look at $QURE and $ABVX this is junk. Keep listening to dumb and dumbers here. This will reverse split and drop another 50%

1 · Reply

Market Cap	3.01B
Revenue (ttm)	27.12M
Net Income (ttm)	-239.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-883.33%
Debt to Equity Ratio	-12.96

Volume	3,570,900
Avg Vol	3,505,632
Day's Range	N/A - N/A
Shares Out	54.87M
Stochastic %K	67%
Beta	0.56
Analysts	Strong Sell
Price Target	$66.55